Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company’), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that Artur Gabor has been appointed as the Company’s Chief Executive Officer with immediate effect.

2022-04-18 PR